Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aegerion Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic disease, has appointed Peter Garrambone, Jr, to its board of directors.
Subscribe to our email newsletter
Mr Garrambone has executed more than 50 pharmaceutical transactions during his 24-year tenure at Pfizer, where he was a senior vice president of corporate strategic planning.
In addition, Aegerion has announced the transition of Jerry Wisler, co- founder, CEO and director of Aegerion, who has left the company to pursue personal interests.
David Scheer, chairman and co-founder of Aegerion, said: “We are fortunate that Peter is joining the board of directors. His extensive strategic and licensing transaction expertise will be invaluable as the company continues the pursuit of its strategic plan with the availability of its important clinical data in November 2008.”